OPEC study: An international multicenter study of ovarian preservation in endometrial cancers.
early-stage
endometrial cancer
ovarian preservation
young women
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
17
02
2022
received:
08
10
2021
accepted:
16
03
2022
pubmed:
25
3
2022
medline:
12
10
2022
entrez:
24
3
2022
Statut:
ppublish
Résumé
To evaluate the feasibility and oncological safety of ovarian preservation in early stage endometrial adenocarcinoma (EC) patients aged 40 and below. A total of 11 institutions from eight countries participated in the study. 169 of 5898 patients aged ≤40 years were eligible for the study. Patients with EC treated between March 2007 and January 2019 were retrospectively assessed. The median duration of follow-up after EC diagnosis was 59 months (4-187). Among 169 participants, ovarian preservation surgery (OPS) was performed in 54 (31.9%), and BSO was performed in 115 (68.1%) patients. Although patients younger than 30 years of age were more likely to have OPS than patients aged 30 to 40 years (20.4% vs. 9.6%, P = 0.021), there was no significant difference by the mean age. There were no other relevant baseline differences between OPS and BSO groups. The Kaplan-Meier analysis revealed no difference in either the overall survival (P = 0.955) or recurrence-free survival (P = 0.068) among patients who underwent OPS, and BSO. OPS appears to be safe without having any adverse impact on survival in women aged ≤40 years with FIGO Stage I EC.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
550-556Informations de copyright
© 2022 International Federation of Gynecology and Obstetrics.
Références
Navarria I, Usel M, Rapiti E, et al. Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment? Gynecol Oncol. 2009;114(3):448-451.
Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2020;31(1):12-39.
Lee TS, Lee JY, Kim JW, et al. Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean gynecologic oncology group study. Gynecol Oncol. 2013;131(2):289-293.
Wright JD, Buck AM, Shah M, Burke WM, Schiff PB, Herzog TJ. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol. 2009;27(8):1214-1219.
Gu H, Li J, Gu Y, Tu H, Zhou Y, Liu J. Survival impact of ovarian preservation on women with early-stage endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2017;27(1):77-84.
Lee TS, Jung JY, Kim JW, et al. Feasibility of ovarian preservation in patients with early stage endometrial carcinoma. Gynecol Oncol. 2007;104(1):52-57.
Lin KY, Miller DS, Bailey AA, et al. Ovarian involvement in endometrioid adenocarcinoma of uterus. Gynecol Oncol. 2015;138(3):532-535.
Sun C, Chen G, Yang Z, et al. Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis. Fertil Steril. 2013;100(3):782-787.
Li L, Wu L, Zhang R, et al. Clinical analysis of ovarian preservation for stage I endometrial carcinomas in women aged 40 years and younger. Zhonghua Fu Chan Ke Za Zhi. 2014;49(4):260-264.
Jia P, Zhang Y. Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer. Oncotarget. 2017;8(35):59940-59949.
Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(2):170-199.
Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16-41.
Wright JD, Jorge S, Tergas AI, et al. Utilization and outcomes of ovarian conservation in premenopausal women with endometrial cancer. Obstet Gynecol. 2016;127(1):101-108.
Gonthier C, Trefoux-Bourdet A, Koskas M. Impact of conservative managements in young women with grade 2 or 3 endometrial adenocarcinoma confined to the endometrium. J Natl Compr Cancer Netw. 2017;27(3):493-499.
Matsuo K, Machida H, Shoupe D, et al. Ovarian conservation and overall survival in young women with early-stage low-grade endometrial cancer. Obstet Gynecol. 2016;128(4):761-770.
Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int. 2008;14(3):111-116.
Bergfeldt K, Einhorn S, Rosendahl I, Hall P. Increased risk of second primary malignancies in patients with gynecological cancer. A Swedish Record-Linkage Study. Acta Oncol. 1995;34(6):771-777.
Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207(4):266.e261-266.e212.
Matsuo K, Machida H, Stone RL, et al. Risk of subsequent ovarian cancer after ovarian conservation in young women with stage I Endometrioid endometrial cancer. Obstet Gynecol. 2017;130(2):403-410.
Shin W, Park S-Y, Kang S, Lim MC, Seo S-S. The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis. J Ovarian Res. 2020;13(1):97.
Kinjyo Y, Kudaka W, Ooyama T, Inamine M, Nagai Y, Aoki Y. Ovarian preservation in young women with endometrial cancer of endometrioid histology. Acta Obstet Gynecol Scand. 2015;94(4):430-434.